

# European Multiple Myeloma Academy

## January 24 – 25, 2020

Venue: Hotel InterContinental Vienna | Johannesgasse 28 | 1030 Vienna, Austria

**Thursday, January 23, 2020**

<b>Dinner Buffet Meeting (registration required)</b>	
<b>19.00</b>	<b>Welcome</b>
<b>19.15 – 20.00</b>	<b>Diagnostic workup of MGUS, SMM and MM, and recommendations for follow-up &amp; question and answers</b>
	<b>Joan Bladé</b>

**Friday, January 24, 2020**

**Main conference room**

<b>8.15 - 8.20</b>	<b>Welcome</b>
	<b>Heinz Ludwig and Jesus San Miguel</b>
<b>8.20 - 8.45</b>	<b>Molecular pathogenesis of multiple myeloma</b>
	<b>Niccolò Bolli</b>
<b>8.45 - 9.10</b>	<b>Molecular profiling of MM, clinical relevance and prospects for the future</b>
	<b>Charlotte Pawlyn</b>
<b>9.10 – 9.35</b>	<b>Next generation flow in monoclonal gammopathies</b>
	<b>Bruno Paiva</b>
<b>9.35 - 10.05</b>	<b>Expert discussion: How to implement this information into clinical practice?</b>
	<b>Moderator: Jesus San Miguel</b> <b>Participants: Charlotte Pawlyn, Bruno Paiva, Niccolò Bolli</b> <ul style="list-style-type: none"> <li>○ What induces progression?</li> <li>○ What do we know about the interplay between immune environment and epigenetics?</li> <li>○ Does immune profiling at baseline inform about prognosis?</li> <li>○ Is MRD assessment ready for use in clinical practice?</li> <li>○ Questions from audience</li> </ul>
<b>10.05 - 10.35</b>	<b>Coffee Break</b>
<b>10.35 – 11.25</b>	
<b>10.35 – 11.25</b>	<b>Workshops</b>
	<ul style="list-style-type: none"> <li>○ Renal disease in multiple myeloma: Pathophysiology and</li> </ul>

	<p><b>treatment</b> <b>Mark Cook</b></p> <ul style="list-style-type: none"> <li>○ <b>Imaging and Management of myeloma bone disease</b> <b>Evangelos Terpos</b></li> <li>○ <b>What you need to know about cytogenetic and molecular risk factors in MM</b> <b>Dirk Hose</b></li> </ul>
<b>11.25 – 11.50</b>	<b>Smoldering myeloma – risk stratification and management</b>
	<b>Marivi Mateos</b>
<b>11.50 - 12.20</b>	<b>Keynote lecture: Aiming for cure of MM. Recent milestones and strategies for the future</b>
	<b>Jesus San Miguel</b>
<b>12.20 – 12.45</b>	<b>Expert discussion- Recent progress and where to go to?</b>
	<b>Moderator-Jesus San Miguel</b> <b>Panelists: Marivi Mateos, Philippe Moreau</b>
	<ul style="list-style-type: none"> <li>○ <b>Should novel cellular immune therapies be integrated in first line treatment</b></li> <li>○ <b>Personalized treatment selection – a realistic expectation?</b></li> <li>○ <b>Which predictive algorithm should be used in SMM?</b></li> <li>○ <b>Questions from the audience</b></li> </ul>
<b>12.45- 13.45</b>	<b>Lunch Buffet</b>
<b>13.45 – 15.15</b>	<b>Mini-Symposium – The transplant eligible patient</b>
<b>13.45 - 14. 10</b>	<b>Is transplant needed for all TE patients?</b>
	<b>Philippe Moreau</b>
<b>14. 10 - 14.35</b>	<b>Established and new options for maintenance therapy</b>
	<b>Michele Cavo</b>
<b>14.35 – 15.00</b>	<b>Expert discussion: Management of TE patients seems to be straight forward, but does this apply to every patient?</b>
	<p><b>Moderator: Philippe Moreau</b> <b>Participants: Michele Cavo, Marivi Mateos, Jesus San Miguel</b></p> <ul style="list-style-type: none"> <li>○ <b>Is splitting cycles to induction and consolidation superior to an equal number of cycles given upfront?</b></li> <li>○ <b>Is there any evidence suggesting switching to another regimen before ASCT if patient do not respond to initial therapy?</b></li> <li>○ <b>First line or delayed ASCT? Any preference depending on</b></li> </ul>

	<p>patient's risk?</p> <ul style="list-style-type: none"> <li>○ What is the optimal maintenance therapy for HR-disease?</li> <li>○ Questions from the audience</li> </ul>
<b>15.00 -15.30</b>	<b>Coffee Break</b>
<b>15.30 – 16.20</b>	<b>Workshops (program repeated)</b>
<b>16.20 – 17.30</b>	<b>Mini-Symposium – Management of transplant-non eligible patients</b>
<b>16.20 – 16.45</b>	<b>Treatment options for elderly fit patients</b>
	<b>Kwee Yong</b>
<b>16.45 – 17.10</b>	<b>Management of elderly, unfit and frail patients</b>
	<b>Alessandra Larocca</b>
<b>17.10 - 17.30</b>	<b>Expert discussion: Management of elderly patients</b>
	<b>Moderator: Heinz Ludwig</b>
	<b>Participants: Kwee Yong, Alessandra Larocca</b>
	<ul style="list-style-type: none"> <li>○ How to improve induction therapy for TNE patients?</li> <li>○ Optimal approach in frail patients?</li> <li>○ Is maintenance therapy a valuable option for elderly patients?</li> <li>○ Strategies for patients not responding to induction?</li> <li>○ Questions from the audience</li> </ul>

**Saturday, January 25, 2020**

<b>Breakfast meeting (registration required)</b>	
<b>7.45 - 8.15</b>	<b>CAR-T cells</b>
	<b>Mohamad Mohty</b>

**Main conference room**

<b>8.30 – 9.50</b>	<b>Minisymposium- Management of high risk and relapsed patients</b>
<b>8.30 – 8.55</b>	<b>Management of genetically defined high risk MM</b>
	<b>Pieter Sonneveld</b>
<b>8.55 – 9.20</b>	<b>Extramedullary disease and plasma cell leukemia</b>
	<b>Francesca Gay</b>
<b>9.20 – 9.50</b>	<b>Management of patients with relapsed disease</b>
	<b>Heinz Ludwig</b>

<b>9.50 -10.15</b>	<b>Expert discussion</b> <b>Moderator: Heinz Ludwig</b> <b>Participants: Pieter Sonneveld, Francesca Gay</b>
	<ul style="list-style-type: none"> <li>○ Can we overcome the negative impact of HR disease with presently available approaches</li> <li>○ Is there a role for aggressive lymphoma type treatment in extramedullary disease?</li> <li>○ Refractoriness – a basket with widely different conditions. How to sort this out?</li> <li>○ Questions from the audience</li> </ul>
<b>10.15– 10.35</b>	<b>Coffee break</b>
<b>10.35 – 11.00</b>	<b>Novel drug targets and therapies</b>
	<b>Enrique Ocio</b>
<b>11.00 – 11.25</b>	<b>BiTEs, antibody conjugates and cellular immunotherapy</b>
	<b>Hermann Einsele</b>
<b>11.25 - 11.55</b>	<b>Expert discussion: Novel treatment approaches</b> <b>Moderator: Hermann Einsele</b> <b>Participants: Mohamad Mothy, Enrice Ocio</b>
	<ul style="list-style-type: none"> <li>○ Varying clonal load, multiple upregulated pathways - is there any realistic chance for long-term success of targeted therapies in MM?</li> <li>○ What is the optimal BM microenvironment for immune therapies</li> <li>○ Progress in cellular therapies is much faster than the time consuming approval process – any clues to overcome this hurdle</li> <li>○ Questions from the audience</li> </ul>
<b>11.55 – 12.20</b>	<b>New developments in Amyloidosis</b>
	<b>Giampaolo Merlini</b>
<b>12.20– 12.30</b>	<b>Closure of the meeting</b>
	<b>Heinz Ludwig</b>

*Program and themes are subject to change!*